Not applicableUnknownNCT05429710What this trial is testingSOX2 & PDL1 Expression on Urinary Bladder CarcinomaWho this might be right forUrinary Bladder Neoplasm Sohag University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03620578What this trial is testingDA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLWho this might be right forNon Hodgkin LymphomaLymphoma, B-CellHigh-grade B-cell Lymphoma+2 more Stichting Hemato-Oncologie voor Volwassenen Nederland 97
Not applicableStudy completedNCT03305133What this trial is testingEvaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)Who this might be right forLarge Cell Lung CancerNeuroendocrine Carcinoma of Lung (Diagnosis) Groupe Francais De Pneumo-Cancerologie 86
Not applicableLooking for participantsNCT06169956What this trial is testingAn Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in GermanyWho this might be right forResectable Non-small Cell Lung Cancer Bristol-Myers Squibb 400
Testing effectiveness (Phase 2)Looking for participantsNCT04107077What this trial is testingPhase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric CancerWho this might be right forGastric CancerPeritoneal Carcinomatosis University of Chicago 21
Large-scale testing (Phase 3)Active Not RecruitingNCT05047250What this trial is testingAtezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Hoffmann-La Roche 60
Not applicableLooking for participantsNCT06177106What this trial is testingSUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of ParticipantsWho this might be right forOther Skin Changes Due to Chronic Exposure to Nonionizing Radiation University of Arizona 46
Not applicableUnknownNCT03820921What this trial is testingEvaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients With Pancreatic CancerWho this might be right forPancreatic Cancer Ponderas Academic Hospital 30
Not applicableStudy completedNCT03433924What this trial is testingAn Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.Who this might be right forUrinary Bladder Cancer AstraZeneca 248
Large-scale testing (Phase 3)Study completedNCT03898180What this trial is testingStudy of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)Who this might be right forUrothelial Carcinoma Merck Sharp & Dohme LLC 505
Large-scale testing (Phase 3)Active Not RecruitingNCT05800015What this trial is testingA Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Regeneron Pharmaceuticals 160
Testing effectiveness (Phase 2)Ended earlyNCT03382912What this trial is testingStudy of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung CancerWho this might be right forNon Small Cell Lung Cancer Eli Lilly and Company 52
Not applicableLooking for participantsNCT07394062What this trial is testingReal-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)Who this might be right forNonsmall Cell Lung Cancer, Stage IVMetastatic Nonsmall Cell Lung Cancer Gazi University 400
Testing effectiveness (Phase 2)UnknownNCT04940637What this trial is testingUNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCWho this might be right forLung CancerMesothelioma University of Turin, Italy 70
Not applicableStudy completedNCT05941676What this trial is testingPrognostic Immune Biomarkers in HNSCCWho this might be right forHead and Neck CancerSquamous Cell Carcinoma University Hospital Ostrava 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06946836What this trial is testingComparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical StudyWho this might be right forResectable Non-small Cell Lung CancerBispecific AntibodyNeoadjuvant Therapy Shanghai Pulmonary Hospital, Shanghai, China 80
Testing effectiveness (Phase 2)Looking for participantsNCT07655622What this trial is testingVebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionWho this might be right forNon-Small-Cell Lung Cancer Second Affiliated Hospital of Nanchang University 45
Very early researchStudy completedNCT03911453What this trial is testingWindow of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsWho this might be right forBreast Cancer University of Arizona 20
Early research (Phase 1)Ended earlyNCT04274907What this trial is testingA Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) ExpressionWho this might be right forNon Small Cell Lung CancerCancer AbbVie 2
Large-scale testing (Phase 3)Study completedNCT03631706What this trial is testingM7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer EMD Serono Research & Development Institute, Inc. 304